Bioxyne Limited, through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
The agreement, signed with Farmakem d.o.o. and Germany-based Adrex Pharmaceuticals GmbH, commits the buyers to purchase and distribute at least 1,600 kilograms of medical cannabis flower product manufactured by BLS under EU Good Manufacturing Practice (GMP) standards.
Adrex is a licensed importer, manufacturer and distributor of cannabis products in Germany.
According to Bioxyne, the agreement marks a key milestone in its international expansion strategy, with initial shipments of 580 kilograms scheduled for September 2025, followed by a second delivery in November.
The company expects to generate a minimum of A$5.6 million in revenue from the deal in the 2026 financial year.
Fourteen Australian-manufactured cannabis strains produced by BLS have been registered with Germany’s Federal Institute for Drugs and Medical Devices (BfArM), authorising their importation and sale within the German market.
Bioxyne said that BLS and Adrex are collaborating to introduce the Dr Watson brand and other BLS products into the region.
The German market is experiencing rapid growth following regulatory changes in early 2025, with expectations it will surpass Australia’s A$1 billion medical cannabis market in 2026.
Bioxyne noted that cannabis flower makes up more than 95% of Germany’s medical cannabis sales and must comply with GMP standards.
As a GMP-certified manufacturer, BLS said it is well-positioned to scale operations and maintain cost advantages as it targets further opportunities in Germany and across the European Union.
Bioxyne anticipates that its entry into Germany, along with planned expansions into the UK and other EU countries, will support substantial growth in FY2026.
